Related Experiment Videos
Androgen-linked alkylating agents: biological activity in methylnitrosourea-induced rat mammary carcinoma
H P Brix1, M R Berger, M R Schneider
1Institute of Toxicology and Chemotherapy, German Cancer Research Center, Heidelberg.
Abstract:
This article gives a comprehensive survey on the anticancer activity of nitrosoureas linked to steroidal androgens in methylnitrosourea (MMU)-induced rat mammary carcinoma. cis-Androsterone, testosterone, 19-nortestosterone and 5-alpha-dihydrotestosterone were used as carrier hormones and were linked to various cytotoxic N-[N'-(2-chloroethyl)-N'-nitrosocarbamoyl] (CNC)-aminoacids and to N-(2-hydroxyethyl)-N'-(2-chloroethyl)-N'-nitrosourea hemisuccinate (HECNU-hemisuccinate). In the MNU-model used esters of dihydrotestosterone (DHT) invariably were more active and less toxic than those of testosterone, nortestosterone and cis-androsterone. Within the DHT esters of CNC-aminoacids those of CNC-glycine, CNC-methionine and CNC-alanine showed the highest antineoplastic activities and superiority compared with equimolar dosages of their unlinked mixtures. Additionally, CNC-alanine-DHT ester had the highest therapeutic ratio of all agents investigated. HECNU-hemisuccinate-DHT ester, on the other hand, achieved even higher antitumor activity at the optimal dose but had a narrower therapeutic ratio. No obvious correlation between antineoplastic efficacy and receptor binding affinity could be demonstrated, but, to be active, a conjugate apparently had to have some receptor binding affinity for both androgen and progesterone receptors. The results obtained indicate that linking antineoplastic agents to transport molecules with affinity to steroid receptors is a highly promising approach to obtain drugs with specific activity in steroid receptor containing tumors.
Insights
Steroidal androgens linked to nitrosoureas show potent anticancer activity against rat mammary tumors. Dihydrotestosterone conjugates demonstrated superior efficacy and reduced toxicity, highlighting a promising drug delivery strategy for steroid receptor-positive cancers.
Area of Science:
- Pharmacology
- Oncology
- Medicinal Chemistry
Background:
- Nitrosoureas are cytotoxic agents with anticancer properties.
- Steroidal androgens can be utilized as carrier molecules for targeted drug delivery.
- Steroid receptor-positive tumors represent a significant therapeutic challenge.
Purpose of the Study:
- To evaluate the anticancer activity of nitrosourea compounds conjugated to steroidal androgens.
- To assess the efficacy and toxicity of these conjugates in a methylnitrosourea (MMU)-induced rat mammary carcinoma model.
- To explore the relationship between receptor binding affinity and antineoplastic efficacy.
Main Methods:
- Synthesis of various cytotoxic N-[N'-(2-chloroethyl)-N'-nitrosocarbamoyl] (CNC)-aminoacids and N-(2-hydroxyethyl)-N'-(2-chloroethyl)-N'-nitrosourea hemisuccinate (HECNU-hemisuccinate) conjugates.
- Steroidal androgens including cis-androsterone, testosterone, 19-nortestosterone, and 5-alpha-dihydrotestosterone (DHT) were used as carrier hormones.
- Evaluation of anticancer activity and toxicity in an MMU-induced rat mammary carcinoma model.
Main Results:
- Esters of dihydrotestosterone (DHT) consistently showed higher activity and lower toxicity compared to other tested steroidal androgens.
- Within DHT esters, CNC-glycine, CNC-methionine, and CNC-alanine conjugates exhibited significant antineoplastic activity, outperforming equimolar unlinked mixtures.
- CNC-alanine-DHT ester displayed the highest therapeutic ratio among all agents, while HECNU-hemisuccinate-DHT ester achieved potent antitumor activity with a narrower therapeutic window.
- Receptor binding affinity for both androgen and progesterone receptors was necessary for activity, though no direct correlation with efficacy was observed.
Conclusions:
- Conjugating antineoplastic agents to steroidal androgens is a promising strategy for developing targeted therapies.
- Dihydrotestosterone conjugates show significant potential for treating steroid receptor-containing tumors.
- Further research into steroid receptor-mediated drug delivery could lead to more effective and specific cancer treatments.